HI
HRTX icon

Harbour Investments’s Heron Therapeutics HRTX Stock Holding History

Harbour Investments’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.67K Buy
4,580
+3,580
+358% +$4.15K ﹤0.01% 3707
2025
Q4 		$1.3K Buy
+1,000
New +$1.24K ﹤0.01% 3403
2021
Q4 		– Sell
-1,188
Closed -$13K – 3099
2021
Q3 		$13K Sell
1,188
-170
-13% -$2.07K ﹤0.01% 2526
2021
Q2 		$21K Sell
1,358
-201
-13% -$3.2K ﹤0.01% 2321
2021
Q1 		$25K Buy
+1,559
New +$27.8K ﹤0.01% 2086

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Harbour Investments's HRTX Position: Q1 2026 in Review

Harbour Investments increased its Heron Therapeutics (HRTX) stake by 358% in Q1 2026, buying an estimated $4.15K and bringing the position to 4,580 shares worth $3.67K. The position accounts for ﹤0.01% of the portfolio, ranked #3707.

Harbour Investments first reported a position in HRTX in Q1 2021 and has held it in 5 quarters since. The position peaked at $25K in Q1 2021. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Harbour Investments held 4,580 shares of Heron Therapeutics worth $3.67K as of Q1 2026.
  • Harbour Investments bought 3,580 Heron Therapeutics shares in Q1 2026, an estimated $4.15K.
  • Heron Therapeutics made up ﹤0.01% of Harbour Investments's portfolio in Q1 2026, its #3707 holding.
  • Harbour Investments first reported a position in Heron Therapeutics in Q1 2021 and has held it in 5 quarters since.
  • Harbour Investments's Heron Therapeutics position peaked at $25K in Q1 2021.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Harbour Investments's 13F filing for Q1 2026, filed 15 May 2026.